Related Experiment Video
Updated: Jun 1, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Hypoglycemia rates with basal insulin analogs
Stuart Little1, James Shaw, Philip Home
1Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, United Kingdom.
Diabetes Technology & Therapeutics
|June 15, 2011
Summary
Long-acting insulin analogs reduce nocturnal hypoglycemia in diabetes. However, current studies inadequately assess hypoglycemia events, limiting understanding for high-risk patients.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Hypoglycemia is a significant concern in insulin therapy for diabetes.
- Existing research often prioritizes glycemic control over hypoglycemia event analysis.
Purpose of the Study:
- To review available hypoglycemia data for long-acting insulin analogs (glargine, detemir) in type 1 and type 2 diabetes.
- To discuss head-to-head comparisons and emerging analogs like degludec regarding hypoglycemia.
Main Methods:
- Review of randomized controlled trials comparing basal insulin analogs (glargine, detemir) with NPH or continuous subcutaneous insulin infusion.
- Analysis of available hypoglycemia data, including limited head-to-head trials.
Main Results:
- Basal insulin analogs are linked to decreased nocturnal hypoglycemia in both type 1 and type 2 diabetes.
- Studies frequently exclude patients with impaired hypoglycemia awareness or prior severe events.
- Hypoglycemia reporting in trials is inconsistent, hindering interpretation.
Conclusions:
- Basal insulin analogs show promise in reducing nocturnal hypoglycemia.
- Further well-designed studies are needed to fully understand the hypoglycemia burden in long-term insulin users, especially those with impaired awareness or advanced diabetes.
More Related Videos
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...